Danaher (DHR)
(Delayed Data from NYSE)
$264.71 USD
+0.22 (0.08%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $263.65 -1.06 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$264.71 USD
+0.22 (0.08%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $263.65 -1.06 (-0.40%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Danaher's Stock Offering Proceeds to Fund BioPharma Buyout
by Zacks Equity Research
Danaher (DHR) successfully completes the offering of common and preferred shares. It intends on using the funds raised to pay for the pending acquisition of General Electric's BioPharma business.
GE Intends to Lower Debt Burden, Boost Dividend Payments
by Zacks Equity Research
General Electric (GE) seeks to become more competent on the back of its initiatives to improve financial position and strengthen core businesses.
Danaher to Buy BioPharma, Offers Common & Preferred Shares
by Zacks Equity Research
Danaher (DHR) to gain from the buyout of the BioPharma business. This is likely to strengthen its biologics workflow solutions business. The company offers common and preferred shares.
General Electric (GE) to Divest BioPharma, Closes Wabtec Deal
by Zacks Equity Research
General Electric (GE) to gain from divestiture of the BioPharma business by using the proceeds to lower debt burden and focus on more important portfolios. It completes GE Transportation divestment.
Company News For Feb 26, 2019
by Zacks Equity Research
Companies In The News Are: DHR,GE,ONCE,CMTA,CRI
Danaher (DHR) Catches Eye: Stock Jumps 8.5%
by Zacks Equity Research
Danaher (DHR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Pre-Markets Up, GE Sells Off Biopharma Biz
by Mark Vickery
With President Trump again delaying the 25% tariff rate and GE raising over $21 billion to pay down debt, futures are in the green this morning.
Positive Development on Trade War Front
by Zacks Equity Research
Positive Development on Trade War Front
Pre-Markets Up, GE Sells Off Biopharma Biz
by Mark Vickery
With President Trump again delaying the 25% tariff rate and GE raising over $21 billion to pay down debt, futures are in the green this morning.
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia
Top Research Reports for ExxonMobil, Merck & Danaher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Merck (MRK) and Danaher (DHR).
CSL or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CSL vs. DHR: Which Stock Is the Better Value Option?
Danaher (DHR) Q4 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
Danaher's (DHR) Q4 earnings jump year over year on the back of solid performance across all its segments.
Danaher (DHR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 0.79% and 0.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
MMM, DHR Q4 Earnings on Jan 29: Here are the Key Predictions
by Zacks Equity Research
Conglomerates sector's earnings are expected to decline year over year in Q4. Read to know how 3M Company (MMM) and Danaher (DHR) are likely to fare.
Can Danaher (DHR) Maintain its Beat Streak in Q4 Earnings?
by Zacks Equity Research
Strength in Life Sciences business, accretive acquisitions and a solid product portfolio are conducive to Danaher's (DHR) likely encouraging Q4 results. However, high cost of sales remains a drag.
CSL or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CSL vs. DHR: Which Stock Is the Better Value Option?
ITT or DHR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITT vs. DHR: Which Stock Is the Better Value Option?
ITT vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
ITT vs. DHR: Which Stock Is the Better Value Option?
Danaher (DHR) Displays Bright Prospects, Headwinds Remain
by Zacks Equity Research
Sturdier demand for innovative products, along with effective implementation of Danaher Business System to boost Danaher's (DHR) revenues despite certain headwinds.
Why Is Danaher (DHR) Up 1.9% Since Last Earnings Report?
by Zacks Equity Research
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What's in the Offing for Macquarie (MIC) in Q3 Earnings?
by Zacks Equity Research
Strong prospects of Macquarie's (MIC) Atlantic Aviation, Contracted Power and MIC Hawaii segments are expected to be conducive to its third-quarter results.
The Zacks Analyst Blog Highlights: Oracle, Netflix, Danaher, State Street and Rogers Communications
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Oracle, Netflix, Danaher, State Street and Rogers Communications
Top Research Reports for Oracle, Netflix & Danaher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Netflix (NFLX) and Danaher (DHR).
Danaher (DHR) Tops Earnings Estimates in Q3, Raises '18 View
by Zacks Equity Research
Danaher's (DHR) Q3 results gain from synergies from acquired assets and core sales growth. The company raises earnings projection for 2018.